Remdesivir is manufactured by Gilead and is used to treat COVID-19. ## Compulsory licenses Compulsory licenses have been issued for Remdesivir in the following instance: ### Hungary issued on March 01, 2020 [[Hungary]]'s provisions on compulsory licences can be in the Hungarian Patent Act, i.e. Act XXXIII of 1995 on the Protection of Inventions by Patents – consolidated text of 1 March 2015. In Hungary, compulsory licences are available on the three grounds: - non-genuine use of the patent (Art. 31 and 33 PA): Art. 31 of the Patent Act specifies that: “If within four years from the date of filing of the patent application or within three years from the grant of the patent, whichever period expires last, the patentee has not exploited the invention in the territory of the country to satisfy the domestic demand or if he has not undertaken serious preparations or has not granted a licence for such purpose, a compulsory licence shall be granted to the applicant for the licence, unless the patentee justifies the lack of exploitation.” - dependency of patents (Art. 32 and 33 PA; also extended to plant varieties Art. 114/B PA); - for the treatment of public health problems (EU Regulation 816/2006, Art. 33/A and 83/A-H PA). More information can be found [here](https://e-courses.epo.org/wbts_int/CompulsoryLicensing/CL_HU.pdf). ## Other products issued by the same manufacturer [[Sofosbuvir]] [[Remdesivir]] ## Other products for the same disease [[LPV/r]]